Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

112 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Lymphoma NCT00290498

- 27/9/21 - 1 formulario, 2 itemgroups, 15 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290498

Eligibility NCT01200758 Non-Hodgkin's Lymphoma - Eligibility

- 27/9/21 - 1 formulario, 2 itemgroups, 10 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01200758

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

- 20/9/21 - 1 formulario, 2 itemgroups, 10 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866047

Eligibility Lymphoma NCT02056548

- 20/9/21 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 20/9/21 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Eligibility Lymphoma NCT00517699

- 20/9/21 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00517699

Advanced B-Cell Leukemia or Lymphoma (NCT00057811) - Reporting Period (ANHL01P1 NCT00057811)

- 20/9/21 - 1 formulario, 5 itemgroups, 70 items, 1 idioma
Itemgroups: Header, Patient characteristics, CNS involvement, Diagnostics and treatment, Lab values
ANHL01P1: Reporting Period Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma NCT00057811 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BA568824-31F6-08D7-E034-0003BA12F5E7

Lymphoma NCT00392834 Demographic - AMC-048 Demographic Form (DEM) - 2655243v1.0 - AMC-048 Demographic Form (DEM)

- 20/9/21 - 1 formulario, 1 itemgroup, 7 items, 1 idioma
Itemgroup: Header
AMC-048 Demographic Form (DEM) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-33B5-4AF2-E044-0003BA3F9857

Eligibility NCT01190449 Lymphoma - CALGB 50901 Eligibility Checklist Form 3211939_v1_0 - CALGB 50901 Eligibility Checklist Form

- 20/9/21 - 1 formulario, 1 itemgroup, 29 items, 2 idiomas
Itemgroup: Eligibility Checklist
CALGB 50901 Eligibility Checklist Form Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F9012C3-FDE5-DB91-E040-BB89AD432434

NCT00057811 CHILDREN'S ONCOLOGY GROUP CYTOGENETICS REPORTING FORM [ANHL01P1]

- 20/9/21 - 1 formulario, 3 itemgroups, 17 items, 1 idioma
Itemgroups: Header, Miscellaneous Patient Information, CCRR MODULE
NCT00057811 CHILDREN'S ONCOLOGY GROUP CYTOGENETICS REPORTING FORM [ANHL01P1] Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BA472941-6B83-4501-E034-0003BA12F5E7

Treatment - Lymphoma - Transplant Treatment Form - 2269914v3.0 - Lymphoma - Transplant Treatment Form

- 17/9/21 - 1 formulario, 6 itemgroups, 65 items, 1 idioma
Itemgroups: CRF Header, Lymphoma: Form Administration, Lymphoma Transplant: Treatment Plan, Lymphoma Transplant: Donor Lymphocyte Infusions, Lymphoma Transplant: Allogeneic - Donor Information, Comments
Lymphoma - Transplant Treatment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5EA8AC6-6F28-703F-E034-0003BA12F5E7

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Patient Enrollment/ Patient Eligibility - Demographics; General Medical History; Prior Therapy; History of Lymphoma

- 18/3/21 - 1 formulario, 13 itemgroups, 46 items, 1 idioma
Itemgroups: Administrative, Demographics (Enrollment), Investigator Signature, For Coulter Use Only, Demographics (General Medical History), Medical History Date, General Medical History, Prior Therapy, Prior Radiation Therapy, History of Lymphoma, Lymphoma Cell Type, Lymphoma Grade , History of Lymphoma
Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial